Sanofi-Aventis Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (6)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (102)
- 2020 (61)
- 2019 (127)
- 2018 (41)
- 2017 (22)
- 2016 (26)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (12)
- 2008 (6)
- 2007 (12)
- 2006 (11)
- 2005 (15)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (9)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (23)
Sponsor content
689 result(s) found, displaying 51 to 60
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Lantus Cartridge.
-
Prescription medicine decision summaryBeyfortus (nirsevimab) is approved for the prevention of respiratory syncytial virus (RSV) in neonates, infants and vulnerable children up to the age of 24 months.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: nirsevimab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Sanofi-Aventis Australia Pty Ltd - Specimen receptacle IVDs.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd